Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy

摘要: The first two patients to be treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL) are reported. One was a 26-year-old Ethiopian man who had been sodium stibogluconate, relapsing visceral (VL), four times between August 2002 and March 2004. In January 2004 this patient found seropositive HIV began antiretroviral treatment stavudine, lamivudine nevirapine. Five months later he developed clinical PKDL, extensive cutaneous, conjunctival oral mucosal involvement. second 42-year-old VL in November 2003. He too subsequently nevirapine from May nodular rash of PKDL over his face upper body 2 weeks after starting the therapy. Treatment both miltefosine, at 100 mg/day 28 days, led complete regression their lesions. When checked 3-6 end miltesofine treatment, neither showed any signs VL, or other HIV-associated disease.